Laura Dunn
Concepts (463)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Informed Consent | 38 | 2017 | 97 | 5.760 |
Why?
| Neoplasms | 49 | 2024 | 1252 | 5.730 |
Why?
| Decision Making | 31 | 2017 | 272 | 3.930 |
Why?
| Depression | 27 | 2024 | 582 | 2.690 |
Why?
| Mental Competency | 23 | 2017 | 33 | 2.600 |
Why?
| Breast Neoplasms | 31 | 2022 | 1200 | 2.540 |
Why?
| Biomedical Research | 14 | 2019 | 246 | 2.210 |
Why?
| Patient Participation | 7 | 2019 | 70 | 2.190 |
Why?
| Anxiety | 15 | 2024 | 285 | 2.190 |
Why?
| Fatigue | 23 | 2023 | 127 | 2.080 |
Why?
| Quality of Life | 28 | 2023 | 852 | 2.070 |
Why?
| Clinical Trials as Topic | 19 | 2023 | 486 | 2.040 |
Why?
| Schizophrenia | 17 | 2008 | 258 | 2.010 |
Why?
| Research Subjects | 12 | 2019 | 51 | 1.960 |
Why?
| Psychiatry | 9 | 2018 | 106 | 1.870 |
Why?
| Patients | 5 | 2022 | 48 | 1.830 |
Why?
| Third-Party Consent | 7 | 2013 | 16 | 1.770 |
Why?
| Middle Aged | 106 | 2024 | 12615 | 1.740 |
Why?
| Female | 134 | 2024 | 27148 | 1.580 |
Why?
| Caregivers | 13 | 2021 | 217 | 1.540 |
Why?
| Stress, Psychological | 12 | 2024 | 266 | 1.540 |
Why?
| Schizophrenic Psychology | 13 | 2011 | 67 | 1.530 |
Why?
| Internship and Residency | 9 | 2011 | 447 | 1.530 |
Why?
| Adaptation, Psychological | 9 | 2024 | 227 | 1.530 |
Why?
| Humans | 178 | 2024 | 50578 | 1.510 |
Why?
| Alzheimer Disease | 8 | 2021 | 316 | 1.510 |
Why?
| Clergy | 3 | 2017 | 24 | 1.500 |
Why?
| Antineoplastic Agents | 14 | 2020 | 1172 | 1.390 |
Why?
| Ethics, Research | 8 | 2016 | 39 | 1.360 |
Why?
| Aged | 81 | 2024 | 9747 | 1.300 |
Why?
| Proxy | 4 | 2013 | 8 | 1.280 |
Why?
| Male | 101 | 2024 | 25923 | 1.240 |
Why?
| Adult | 69 | 2024 | 13604 | 1.220 |
Why?
| Mental Disorders | 9 | 2019 | 415 | 1.220 |
Why?
| Depressive Disorder | 10 | 2023 | 335 | 1.200 |
Why?
| Psychotherapy | 5 | 2014 | 110 | 1.180 |
Why?
| Cognition Disorders | 11 | 2021 | 213 | 1.150 |
Why?
| Psychotic Disorders | 10 | 2018 | 136 | 1.140 |
Why?
| Comprehension | 7 | 2016 | 116 | 1.070 |
Why?
| Spiritual Therapies | 2 | 2017 | 6 | 1.030 |
Why?
| Patient Preference | 2 | 2016 | 40 | 1.020 |
Why?
| Cytokines | 10 | 2017 | 606 | 1.000 |
Why?
| Longitudinal Studies | 33 | 2024 | 737 | 0.970 |
Why?
| Palliative Care | 3 | 2017 | 190 | 0.960 |
Why?
| Dementia | 3 | 2017 | 148 | 0.950 |
Why?
| Education | 4 | 2011 | 42 | 0.920 |
Why?
| Personality | 2 | 2022 | 28 | 0.880 |
Why?
| Therapeutic Misconception | 4 | 2017 | 4 | 0.840 |
Why?
| Ambulatory Care | 8 | 2017 | 230 | 0.830 |
Why?
| Aged, 80 and over | 26 | 2020 | 3227 | 0.830 |
Why?
| Genetic Research | 2 | 2019 | 4 | 0.820 |
Why?
| Mastectomy | 8 | 2021 | 142 | 0.800 |
Why?
| Attitude of Health Personnel | 3 | 2011 | 352 | 0.780 |
Why?
| Psychiatric Status Rating Scales | 9 | 2017 | 318 | 0.750 |
Why?
| Polymorphism, Single Nucleotide | 14 | 2017 | 474 | 0.740 |
Why?
| Severity of Illness Index | 24 | 2019 | 978 | 0.730 |
Why?
| Patient Rights | 2 | 2019 | 3 | 0.710 |
Why?
| Mental Health | 5 | 2016 | 228 | 0.700 |
Why?
| Radiotherapy | 3 | 2018 | 125 | 0.690 |
Why?
| Geriatric Psychiatry | 3 | 2017 | 9 | 0.680 |
Why?
| Self Concept | 1 | 2020 | 65 | 0.670 |
Why?
| Deep Brain Stimulation | 4 | 2014 | 43 | 0.650 |
Why?
| Health Services Research | 4 | 2016 | 152 | 0.620 |
Why?
| Attention Deficit Disorder with Hyperactivity | 1 | 2020 | 172 | 0.620 |
Why?
| Choroid Neoplasms | 1 | 2018 | 6 | 0.600 |
Why?
| Eye Enucleation | 1 | 2018 | 11 | 0.590 |
Why?
| Anxiety Disorders | 5 | 2022 | 123 | 0.590 |
Why?
| Patient Selection | 7 | 2016 | 259 | 0.580 |
Why?
| Pain | 10 | 2023 | 387 | 0.570 |
Why?
| Comorbidity | 12 | 2021 | 624 | 0.560 |
Why?
| Resilience, Psychological | 4 | 2024 | 23 | 0.560 |
Why?
| Needs Assessment | 3 | 2015 | 136 | 0.560 |
Why?
| Self Report | 13 | 2021 | 206 | 0.540 |
Why?
| Circadian Rhythm | 5 | 2016 | 89 | 0.530 |
Why?
| Outpatients | 9 | 2022 | 117 | 0.530 |
Why?
| Genetic Variation | 4 | 2014 | 208 | 0.520 |
Why?
| Syndrome | 6 | 2023 | 240 | 0.510 |
Why?
| Genetics | 2 | 2018 | 6 | 0.500 |
Why?
| Chaplaincy Service, Hospital | 1 | 2015 | 1 | 0.490 |
Why?
| Risk Assessment | 7 | 2014 | 1269 | 0.490 |
Why?
| Interdisciplinary Studies | 1 | 2015 | 4 | 0.490 |
Why?
| Research | 3 | 2006 | 106 | 0.490 |
Why?
| Cross-Sectional Studies | 12 | 2022 | 1611 | 0.480 |
Why?
| Melanoma | 1 | 2018 | 280 | 0.470 |
Why?
| Aging | 5 | 2015 | 694 | 0.470 |
Why?
| Mastodynia | 5 | 2016 | 6 | 0.460 |
Why?
| Internet | 3 | 2016 | 259 | 0.450 |
Why?
| Fear | 1 | 2014 | 84 | 0.440 |
Why?
| Survivors | 1 | 2014 | 127 | 0.440 |
Why?
| Patient Education as Topic | 4 | 2011 | 320 | 0.430 |
Why?
| Research Personnel | 5 | 2019 | 65 | 0.420 |
Why?
| Clinical Competence | 4 | 2011 | 398 | 0.420 |
Why?
| Health Knowledge, Attitudes, Practice | 3 | 2016 | 491 | 0.410 |
Why?
| Motivation | 2 | 2021 | 275 | 0.410 |
Why?
| Physician-Patient Relations | 3 | 2016 | 142 | 0.410 |
Why?
| Chronic Pain | 3 | 2023 | 182 | 0.410 |
Why?
| Interleukin-6 | 5 | 2014 | 262 | 0.400 |
Why?
| Patient Care Team | 1 | 2014 | 258 | 0.390 |
Why?
| Disclosure | 1 | 2012 | 39 | 0.390 |
Why?
| Symptom Assessment | 5 | 2018 | 32 | 0.390 |
Why?
| Pilot Projects | 8 | 2022 | 702 | 0.370 |
Why?
| Prostatic Neoplasms | 5 | 2013 | 384 | 0.360 |
Why?
| Risk Factors | 15 | 2022 | 3724 | 0.350 |
Why?
| Neoplasm Recurrence, Local | 1 | 2014 | 629 | 0.350 |
Why?
| Ethics Committees, Research | 3 | 2019 | 15 | 0.350 |
Why?
| Patient Acceptance of Health Care | 2 | 2016 | 346 | 0.350 |
Why?
| Socioeconomic Factors | 5 | 2017 | 594 | 0.330 |
Why?
| Attitude | 3 | 2018 | 69 | 0.320 |
Why?
| Medical Oncology | 4 | 2021 | 98 | 0.320 |
Why?
| Prevalence | 11 | 2020 | 972 | 0.320 |
Why?
| Parents | 1 | 2012 | 318 | 0.320 |
Why?
| Attention | 4 | 2014 | 172 | 0.320 |
Why?
| Gastrointestinal Neoplasms | 2 | 2021 | 40 | 0.320 |
Why?
| Clinical Protocols | 2 | 2006 | 110 | 0.320 |
Why?
| Faculty, Medical | 1 | 2010 | 92 | 0.320 |
Why?
| California | 9 | 2020 | 86 | 0.300 |
Why?
| Sleep | 4 | 2022 | 184 | 0.300 |
Why?
| Smoking Cessation | 1 | 2011 | 303 | 0.300 |
Why?
| Cognition | 2 | 2020 | 346 | 0.300 |
Why?
| Student Health Services | 1 | 2008 | 7 | 0.290 |
Why?
| Multimedia | 3 | 2017 | 4 | 0.290 |
Why?
| Age Factors | 12 | 2016 | 1111 | 0.290 |
Why?
| Wakefulness | 3 | 2012 | 49 | 0.280 |
Why?
| Burnout, Professional | 1 | 2008 | 52 | 0.280 |
Why?
| Neuropsychological Tests | 3 | 2012 | 355 | 0.280 |
Why?
| Young Adult | 12 | 2020 | 4113 | 0.280 |
Why?
| Academic Medical Centers | 1 | 2008 | 149 | 0.270 |
Why?
| Choice Behavior | 1 | 2008 | 83 | 0.270 |
Why?
| Aptitude | 1 | 2006 | 4 | 0.270 |
Why?
| Genotype | 8 | 2015 | 532 | 0.260 |
Why?
| Life Change Events | 2 | 2017 | 36 | 0.260 |
Why?
| Factor Analysis, Statistical | 8 | 2017 | 78 | 0.260 |
Why?
| United States | 16 | 2020 | 4964 | 0.250 |
Why?
| Placebos | 1 | 2005 | 87 | 0.250 |
Why?
| Randomized Controlled Trials as Topic | 5 | 2016 | 574 | 0.250 |
Why?
| Phenotype | 8 | 2016 | 739 | 0.250 |
Why?
| Students, Medical | 1 | 2008 | 162 | 0.250 |
Why?
| Tenosynovitis | 1 | 2005 | 6 | 0.250 |
Why?
| Health Promotion | 1 | 2008 | 258 | 0.240 |
Why?
| Tendons | 1 | 2005 | 27 | 0.240 |
Why?
| Reimbursement, Incentive | 1 | 2005 | 13 | 0.240 |
Why?
| Foot | 1 | 2005 | 40 | 0.240 |
Why?
| Emotions | 3 | 2020 | 167 | 0.220 |
Why?
| Research Design | 7 | 2012 | 353 | 0.220 |
Why?
| Prospective Studies | 11 | 2021 | 2383 | 0.220 |
Why?
| Health Status | 5 | 2023 | 299 | 0.220 |
Why?
| Hospice Care | 3 | 2012 | 26 | 0.220 |
Why?
| Psychosocial Deprivation | 1 | 2003 | 2 | 0.220 |
Why?
| Cohort Studies | 5 | 2020 | 1456 | 0.220 |
Why?
| Head Injuries, Closed | 1 | 2003 | 8 | 0.220 |
Why?
| Random Allocation | 3 | 2017 | 289 | 0.220 |
Why?
| Interviews as Topic | 3 | 2013 | 272 | 0.220 |
Why?
| Ethics, Clinical | 1 | 2003 | 12 | 0.220 |
Why?
| Patient Care | 1 | 2003 | 58 | 0.210 |
Why?
| Pain, Postoperative | 3 | 2014 | 163 | 0.210 |
Why?
| Follow-Up Studies | 4 | 2018 | 2243 | 0.210 |
Why?
| Psychometrics | 5 | 2007 | 232 | 0.210 |
Why?
| Genetic Predisposition to Disease | 4 | 2014 | 510 | 0.210 |
Why?
| Genital Neoplasms, Female | 1 | 2023 | 41 | 0.210 |
Why?
| Analysis of Variance | 6 | 2013 | 553 | 0.200 |
Why?
| Promoter Regions, Genetic | 3 | 2013 | 465 | 0.200 |
Why?
| Reproducibility of Results | 5 | 2024 | 1203 | 0.190 |
Why?
| Career Choice | 1 | 2003 | 112 | 0.190 |
Why?
| Tumor Necrosis Factor-alpha | 3 | 2014 | 393 | 0.190 |
Why?
| Data Collection | 4 | 2011 | 280 | 0.190 |
Why?
| Antipsychotic Agents | 4 | 2006 | 233 | 0.190 |
Why?
| Sick Role | 1 | 2001 | 13 | 0.190 |
Why?
| Chi-Square Distribution | 5 | 2015 | 277 | 0.190 |
Why?
| Vulnerable Populations | 2 | 2011 | 47 | 0.180 |
Why?
| Transcranial Magnetic Stimulation | 1 | 2021 | 70 | 0.180 |
Why?
| Mood Disorders | 1 | 2021 | 58 | 0.180 |
Why?
| Pregnancy Trimester, First | 1 | 2020 | 22 | 0.180 |
Why?
| Physical Endurance | 1 | 2020 | 31 | 0.180 |
Why?
| Age Distribution | 4 | 2014 | 171 | 0.180 |
Why?
| Antibodies, Neutralizing | 1 | 2020 | 62 | 0.170 |
Why?
| Antibodies, Viral | 1 | 2020 | 93 | 0.170 |
Why?
| Algorithms | 1 | 2024 | 631 | 0.170 |
Why?
| Social Support | 3 | 2015 | 266 | 0.170 |
Why?
| Self Efficacy | 1 | 2001 | 131 | 0.170 |
Why?
| Immunoglobulin G | 1 | 2020 | 190 | 0.170 |
Why?
| Epigenesis, Genetic | 1 | 2023 | 372 | 0.160 |
Why?
| Population Surveillance | 1 | 2020 | 164 | 0.160 |
Why?
| Pregnancy Complications, Infectious | 1 | 2020 | 75 | 0.160 |
Why?
| Constipation | 1 | 2019 | 34 | 0.160 |
Why?
| Taste | 1 | 2019 | 29 | 0.160 |
Why?
| Employment | 1 | 2020 | 90 | 0.160 |
Why?
| Family | 4 | 2015 | 178 | 0.160 |
Why?
| Breast | 2 | 2021 | 85 | 0.160 |
Why?
| Feasibility Studies | 4 | 2016 | 394 | 0.160 |
Why?
| Health Services Accessibility | 1 | 2003 | 428 | 0.160 |
Why?
| Diarrhea | 1 | 2019 | 90 | 0.160 |
Why?
| Abdominal Pain | 1 | 2019 | 83 | 0.150 |
Why?
| Premenopause | 1 | 2018 | 26 | 0.150 |
Why?
| Specialties, Nursing | 1 | 1998 | 3 | 0.150 |
Why?
| Adolescent | 8 | 2020 | 6447 | 0.150 |
Why?
| Ruthenium Radioisotopes | 1 | 2018 | 2 | 0.150 |
Why?
| Professional Autonomy | 1 | 1998 | 7 | 0.150 |
Why?
| Logistic Models | 4 | 2013 | 899 | 0.150 |
Why?
| Lung Neoplasms | 2 | 2017 | 600 | 0.150 |
Why?
| Proton Therapy | 1 | 2018 | 11 | 0.150 |
Why?
| Career Mobility | 1 | 1998 | 28 | 0.150 |
Why?
| Cholinergic Agents | 1 | 2017 | 5 | 0.150 |
Why?
| Education, Nursing, Graduate | 1 | 1998 | 20 | 0.150 |
Why?
| Brachytherapy | 1 | 2018 | 46 | 0.150 |
Why?
| Social Stigma | 1 | 2018 | 47 | 0.140 |
Why?
| Postmenopause | 1 | 2018 | 96 | 0.140 |
Why?
| Postoperative Period | 2 | 2014 | 171 | 0.140 |
Why?
| Substance-Related Disorders | 1 | 2003 | 611 | 0.140 |
Why?
| Pneumonia, Viral | 1 | 2020 | 169 | 0.140 |
Why?
| Actigraphy | 6 | 2012 | 23 | 0.140 |
Why?
| Spirituality | 1 | 2017 | 30 | 0.140 |
Why?
| Antibodies | 1 | 2017 | 153 | 0.140 |
Why?
| Menopause | 1 | 2017 | 55 | 0.140 |
Why?
| Skin Aging | 1 | 1997 | 9 | 0.140 |
Why?
| Coronavirus Infections | 1 | 2020 | 178 | 0.140 |
Why?
| Janus Kinases | 1 | 2017 | 7 | 0.140 |
Why?
| STAT Transcription Factors | 1 | 2017 | 8 | 0.140 |
Why?
| Education, Medical, Graduate | 2 | 2011 | 217 | 0.140 |
Why?
| Specialization | 1 | 2017 | 46 | 0.140 |
Why?
| Sex Characteristics | 3 | 2015 | 198 | 0.130 |
Why?
| Multivariate Analysis | 3 | 2013 | 583 | 0.130 |
Why?
| Hand Strength | 1 | 2016 | 22 | 0.130 |
Why?
| Certification | 1 | 2017 | 49 | 0.130 |
Why?
| Upper Extremity | 1 | 2016 | 43 | 0.130 |
Why?
| Depression, Postpartum | 1 | 2016 | 43 | 0.130 |
Why?
| Inflammasomes | 1 | 2017 | 62 | 0.130 |
Why?
| Sex Distribution | 2 | 2014 | 136 | 0.130 |
Why?
| Range of Motion, Articular | 1 | 2016 | 108 | 0.130 |
Why?
| Pandemics | 1 | 2020 | 568 | 0.130 |
Why?
| Survival Analysis | 1 | 2017 | 661 | 0.130 |
Why?
| Health Services Needs and Demand | 2 | 2014 | 156 | 0.130 |
Why?
| Estrogens | 1 | 1997 | 226 | 0.120 |
Why?
| Pain Measurement | 5 | 2015 | 271 | 0.120 |
Why?
| NF-kappa B | 1 | 2017 | 315 | 0.120 |
Why?
| Cluster Analysis | 3 | 2023 | 219 | 0.120 |
Why?
| Potassium Channels | 1 | 2015 | 33 | 0.120 |
Why?
| Serotonin Agents | 1 | 2014 | 13 | 0.120 |
Why?
| Curriculum | 4 | 2011 | 400 | 0.120 |
Why?
| Risk | 2 | 2016 | 324 | 0.120 |
Why?
| Catecholamines | 1 | 2014 | 47 | 0.120 |
Why?
| Individuality | 3 | 2021 | 30 | 0.120 |
Why?
| Treatment Refusal | 2 | 2006 | 35 | 0.120 |
Why?
| Professional Role | 1 | 2015 | 77 | 0.120 |
Why?
| Terminal Care | 1 | 2015 | 46 | 0.120 |
Why?
| Receptors, Interferon | 1 | 2014 | 4 | 0.110 |
Why?
| Regression Analysis | 5 | 2015 | 382 | 0.110 |
Why?
| gamma-Aminobutyric Acid | 1 | 2014 | 65 | 0.110 |
Why?
| Sex Factors | 5 | 2020 | 711 | 0.110 |
Why?
| Lymph Node Excision | 3 | 2021 | 131 | 0.110 |
Why?
| Models, Statistical | 2 | 2012 | 226 | 0.110 |
Why?
| Receptors, Interleukin-1 Type I | 1 | 2013 | 2 | 0.110 |
Why?
| Educational Status | 3 | 2020 | 230 | 0.110 |
Why?
| Drug Therapy | 2 | 2006 | 47 | 0.110 |
Why?
| Australia | 4 | 2015 | 86 | 0.110 |
Why?
| Incidence | 3 | 2013 | 1032 | 0.110 |
Why?
| Home Care Services | 1 | 2015 | 73 | 0.110 |
Why?
| NF-kappa B p52 Subunit | 1 | 2013 | 6 | 0.110 |
Why?
| Chemotherapy, Adjuvant | 4 | 2017 | 121 | 0.110 |
Why?
| Linear Models | 4 | 2020 | 279 | 0.110 |
Why?
| Guidelines as Topic | 2 | 2013 | 109 | 0.100 |
Why?
| Health Services, Indigenous | 1 | 2012 | 5 | 0.100 |
Why?
| Allied Health Occupations | 1 | 2012 | 9 | 0.100 |
Why?
| Affect | 2 | 2023 | 103 | 0.100 |
Why?
| Activity Cycles | 1 | 2012 | 4 | 0.100 |
Why?
| Genetic Association Studies | 4 | 2014 | 119 | 0.100 |
Why?
| Diagnostic Self Evaluation | 1 | 2011 | 14 | 0.100 |
Why?
| Quality Assurance, Health Care | 1 | 2012 | 150 | 0.090 |
Why?
| Treatment Failure | 1 | 2011 | 118 | 0.090 |
Why?
| Inflammation Mediators | 1 | 2012 | 111 | 0.090 |
Why?
| Societies, Medical | 1 | 2012 | 187 | 0.090 |
Why?
| Preoperative Period | 3 | 2018 | 48 | 0.090 |
Why?
| Postoperative Complications | 2 | 2016 | 1034 | 0.090 |
Why?
| Psychopharmacology | 1 | 2011 | 5 | 0.090 |
Why?
| Suicide | 2 | 2009 | 83 | 0.090 |
Why?
| Gene Expression Profiling | 1 | 2016 | 1025 | 0.090 |
Why?
| Family Relations | 1 | 2011 | 23 | 0.090 |
Why?
| Time Factors | 6 | 2017 | 2939 | 0.090 |
Why?
| Ethics, Medical | 1 | 2011 | 46 | 0.090 |
Why?
| Psychotropic Drugs | 1 | 2011 | 76 | 0.090 |
Why?
| Evidence-Based Practice | 1 | 2011 | 98 | 0.090 |
Why?
| Inpatients | 1 | 2011 | 193 | 0.080 |
Why?
| Patient Satisfaction | 1 | 2011 | 280 | 0.080 |
Why?
| England | 2 | 2020 | 45 | 0.080 |
Why?
| Case-Control Studies | 4 | 2017 | 1158 | 0.080 |
Why?
| Knowledge | 2 | 2007 | 28 | 0.080 |
Why?
| Inflammation | 2 | 2012 | 610 | 0.080 |
Why?
| Government Regulation | 1 | 2009 | 14 | 0.080 |
Why?
| New Mexico | 1 | 2009 | 13 | 0.080 |
Why?
| Predictive Value of Tests | 3 | 2012 | 932 | 0.080 |
Why?
| Pregnancy | 3 | 2020 | 2504 | 0.080 |
Why?
| Combined Modality Therapy | 1 | 2011 | 641 | 0.080 |
Why?
| Prejudice | 1 | 2009 | 39 | 0.080 |
Why?
| Terminally Ill | 1 | 2008 | 13 | 0.080 |
Why?
| Mental Health Services | 1 | 2011 | 202 | 0.080 |
Why?
| Karnofsky Performance Status | 3 | 2012 | 9 | 0.080 |
Why?
| Attitude to Health | 1 | 2010 | 193 | 0.080 |
Why?
| Demography | 2 | 2022 | 94 | 0.070 |
Why?
| Axilla | 2 | 2020 | 91 | 0.070 |
Why?
| Smoking | 1 | 2011 | 508 | 0.070 |
Why?
| Cross-Cultural Comparison | 1 | 2007 | 26 | 0.070 |
Why?
| Mentors | 1 | 2008 | 55 | 0.070 |
Why?
| Brain Neoplasms | 1 | 2011 | 291 | 0.070 |
Why?
| Mass Screening | 2 | 2007 | 344 | 0.070 |
Why?
| Reference Standards | 1 | 2006 | 52 | 0.070 |
Why?
| Decision Support Techniques | 1 | 2007 | 70 | 0.070 |
Why?
| Problem Solving | 1 | 2006 | 43 | 0.070 |
Why?
| Statistics as Topic | 1 | 2006 | 89 | 0.070 |
Why?
| Prognosis | 3 | 2018 | 1978 | 0.060 |
Why?
| Human Experimentation | 1 | 2005 | 11 | 0.060 |
Why?
| Hallux Rigidus | 1 | 2005 | 1 | 0.060 |
Why?
| Delivery of Health Care | 2 | 2024 | 306 | 0.060 |
Why?
| Bipolar Disorder | 1 | 2007 | 195 | 0.060 |
Why?
| Models, Economic | 1 | 2005 | 17 | 0.060 |
Why?
| Infant, Newborn | 1 | 2012 | 2768 | 0.060 |
Why?
| Exercise Therapy | 1 | 2005 | 96 | 0.060 |
Why?
| Treatment Outcome | 5 | 2018 | 5284 | 0.060 |
Why?
| Primary Health Care | 1 | 2008 | 366 | 0.060 |
Why?
| Haplotypes | 2 | 2014 | 83 | 0.060 |
Why?
| Sensitivity and Specificity | 3 | 2016 | 862 | 0.060 |
Why?
| Scotland | 1 | 2003 | 4 | 0.050 |
Why?
| Abbreviated Injury Scale | 1 | 2003 | 6 | 0.050 |
Why?
| Patient Care Planning | 1 | 2004 | 66 | 0.050 |
Why?
| Pain Management | 1 | 2005 | 180 | 0.050 |
Why?
| Bioethical Issues | 1 | 2003 | 10 | 0.050 |
Why?
| Multiple Trauma | 1 | 2003 | 33 | 0.050 |
Why?
| Causality | 2 | 2014 | 47 | 0.050 |
Why?
| Personal Satisfaction | 1 | 2023 | 79 | 0.050 |
Why?
| Grief | 1 | 2002 | 9 | 0.050 |
Why?
| Disease Progression | 2 | 2017 | 829 | 0.050 |
Why?
| Neurosurgical Procedures | 1 | 2003 | 124 | 0.050 |
Why?
| Antigen Presentation | 1 | 2001 | 25 | 0.050 |
Why?
| Immune Tolerance | 1 | 2001 | 84 | 0.050 |
Why?
| Qualitative Research | 1 | 2024 | 350 | 0.050 |
Why?
| Reference Values | 1 | 2002 | 308 | 0.050 |
Why?
| Alleles | 2 | 2013 | 255 | 0.050 |
Why?
| Polymorphism, Genetic | 2 | 2014 | 180 | 0.050 |
Why?
| Hospital Mortality | 1 | 2003 | 413 | 0.050 |
Why?
| Antigens, Neoplasm | 1 | 2001 | 148 | 0.050 |
Why?
| Survival Rate | 1 | 2003 | 909 | 0.040 |
Why?
| Seroepidemiologic Studies | 1 | 2020 | 48 | 0.040 |
Why?
| Motor Activity | 2 | 2012 | 225 | 0.040 |
Why?
| Single-Blind Method | 1 | 2020 | 114 | 0.040 |
Why?
| Patient Compliance | 1 | 2002 | 233 | 0.040 |
Why?
| Ossification, Heterotopic | 1 | 2000 | 8 | 0.040 |
Why?
| Databases, Factual | 1 | 2003 | 673 | 0.040 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 234 | 0.040 |
Why?
| Religion | 1 | 2020 | 62 | 0.040 |
Why?
| Prenatal Diagnosis | 1 | 2020 | 103 | 0.040 |
Why?
| ROC Curve | 2 | 2012 | 228 | 0.040 |
Why?
| Mastectomy, Segmental | 1 | 2020 | 93 | 0.040 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2005 | 519 | 0.040 |
Why?
| Sentinel Lymph Node Biopsy | 1 | 2020 | 118 | 0.040 |
Why?
| Clozapine | 1 | 1999 | 26 | 0.040 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2000 | 121 | 0.040 |
Why?
| DNA Methylation | 1 | 2023 | 550 | 0.040 |
Why?
| Job Description | 1 | 1998 | 8 | 0.040 |
Why?
| Training Support | 1 | 1998 | 10 | 0.040 |
Why?
| Population Groups | 1 | 2018 | 6 | 0.040 |
Why?
| Professional Competence | 1 | 1998 | 40 | 0.040 |
Why?
| Morals | 1 | 2018 | 47 | 0.040 |
Why?
| Drugs, Investigational | 1 | 2017 | 14 | 0.040 |
Why?
| School Admission Criteria | 1 | 1998 | 35 | 0.040 |
Why?
| Amyloid | 1 | 2017 | 30 | 0.040 |
Why?
| Hypesthesia | 1 | 2017 | 17 | 0.040 |
Why?
| Nausea | 1 | 2017 | 45 | 0.040 |
Why?
| Back Pain | 1 | 2017 | 38 | 0.040 |
Why?
| Consent Forms | 1 | 2016 | 6 | 0.030 |
Why?
| Mammaplasty | 1 | 2016 | 44 | 0.030 |
Why?
| Periodicity | 1 | 2016 | 23 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2016 | 232 | 0.030 |
Why?
| Arthroplasty, Replacement, Hip | 1 | 2000 | 263 | 0.030 |
Why?
| Health Surveys | 1 | 1997 | 239 | 0.030 |
Why?
| Immunotherapy | 1 | 2017 | 235 | 0.030 |
Why?
| Executive Function | 1 | 2016 | 76 | 0.030 |
Why?
| Geriatric Assessment | 1 | 2016 | 116 | 0.030 |
Why?
| Veterans | 1 | 2002 | 574 | 0.030 |
Why?
| Fellowships and Scholarships | 1 | 2017 | 120 | 0.030 |
Why?
| Neoadjuvant Therapy | 1 | 2016 | 120 | 0.030 |
Why?
| Hospitalization | 3 | 2008 | 676 | 0.030 |
Why?
| Signal Transduction | 1 | 2001 | 1624 | 0.030 |
Why?
| Forecasting | 1 | 2015 | 147 | 0.030 |
Why?
| Time | 1 | 2014 | 28 | 0.030 |
Why?
| Disability Evaluation | 1 | 2014 | 93 | 0.030 |
Why?
| Magnetic Resonance Imaging | 1 | 2001 | 1548 | 0.030 |
Why?
| Genetic Testing | 1 | 2015 | 120 | 0.030 |
Why?
| Data Interpretation, Statistical | 1 | 2015 | 163 | 0.030 |
Why?
| National Institute of Mental Health (U.S.) | 1 | 2013 | 2 | 0.030 |
Why?
| Genetic Markers | 1 | 2014 | 104 | 0.030 |
Why?
| Homozygote | 1 | 2013 | 56 | 0.030 |
Why?
| Heterozygote | 1 | 2013 | 83 | 0.030 |
Why?
| Cancer Care Facilities | 1 | 2013 | 18 | 0.030 |
Why?
| Urination | 1 | 2013 | 19 | 0.030 |
Why?
| Sexuality | 1 | 2013 | 13 | 0.030 |
Why?
| Watchful Waiting | 1 | 2013 | 26 | 0.030 |
Why?
| Brain | 1 | 2001 | 1339 | 0.030 |
Why?
| Exercise | 1 | 2017 | 516 | 0.030 |
Why?
| Prostatectomy | 1 | 2013 | 82 | 0.030 |
Why?
| Ambulatory Care Facilities | 1 | 2013 | 121 | 0.030 |
Why?
| Queensland | 1 | 2012 | 3 | 0.030 |
Why?
| Canada | 1 | 2013 | 105 | 0.030 |
Why?
| San Francisco | 1 | 2012 | 12 | 0.030 |
Why?
| Disorders of Excessive Somnolence | 1 | 2012 | 7 | 0.030 |
Why?
| Sleep Stages | 1 | 2012 | 42 | 0.030 |
Why?
| Interleukin-18 Receptor alpha Subunit | 1 | 2012 | 1 | 0.030 |
Why?
| Interleukin-3 | 1 | 2012 | 13 | 0.030 |
Why?
| Preoperative Care | 1 | 2013 | 169 | 0.020 |
Why?
| Women's Health | 1 | 2012 | 85 | 0.020 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 833 | 0.020 |
Why?
| Models, Theoretical | 1 | 2012 | 170 | 0.020 |
Why?
| Interview, Psychological | 1 | 2011 | 22 | 0.020 |
Why?
| Odds Ratio | 1 | 2013 | 551 | 0.020 |
Why?
| Goals | 1 | 2011 | 44 | 0.020 |
Why?
| Rest | 1 | 2011 | 62 | 0.020 |
Why?
| Polysomnography | 1 | 2010 | 71 | 0.020 |
Why?
| Schools, Medical | 1 | 2011 | 71 | 0.020 |
Why?
| Models, Biological | 1 | 2013 | 716 | 0.020 |
Why?
| Cost of Illness | 1 | 2011 | 114 | 0.020 |
Why?
| Gene Frequency | 1 | 2010 | 96 | 0.020 |
Why?
| Nursing Methodology Research | 1 | 2010 | 33 | 0.020 |
Why?
| Tourette Syndrome | 1 | 2009 | 10 | 0.020 |
Why?
| Clinical Nursing Research | 1 | 2009 | 10 | 0.020 |
Why?
| Obsessive-Compulsive Disorder | 1 | 2009 | 44 | 0.020 |
Why?
| Electroencephalography | 1 | 2010 | 310 | 0.020 |
Why?
| Personality Disorders | 1 | 2008 | 20 | 0.020 |
Why?
| Federal Government | 1 | 2008 | 4 | 0.020 |
Why?
| Virginia | 1 | 2008 | 19 | 0.020 |
Why?
| Sleep Initiation and Maintenance Disorders | 1 | 2008 | 43 | 0.020 |
Why?
| Credentialing | 1 | 2007 | 8 | 0.020 |
Why?
| Bioethics | 1 | 2007 | 14 | 0.020 |
Why?
| Matched-Pair Analysis | 1 | 2007 | 11 | 0.020 |
Why?
| Audiovisual Aids | 1 | 2007 | 12 | 0.020 |
Why?
| Quality of Health Care | 1 | 2008 | 184 | 0.020 |
Why?
| Reading | 1 | 2007 | 85 | 0.020 |
Why?
| Empiricism | 1 | 2005 | 1 | 0.020 |
Why?
| Chronic Disease | 1 | 2008 | 574 | 0.020 |
Why?
| Length of Stay | 1 | 2008 | 629 | 0.010 |
Why?
| Intelligence Tests | 1 | 2004 | 44 | 0.010 |
Why?
| Interdisciplinary Communication | 1 | 2003 | 53 | 0.010 |
Why?
| Advisory Committees | 1 | 2003 | 65 | 0.010 |
Why?
| Bereavement | 1 | 2002 | 13 | 0.010 |
Why?
| Probability | 1 | 2002 | 164 | 0.010 |
Why?
| Listeriosis | 1 | 2001 | 7 | 0.010 |
Why?
| Papillomavirus E7 Proteins | 1 | 2001 | 31 | 0.010 |
Why?
| Antigens, Bacterial | 1 | 2001 | 51 | 0.010 |
Why?
| Injections, Intravenous | 1 | 2001 | 137 | 0.010 |
Why?
| Keratinocytes | 1 | 2001 | 77 | 0.010 |
Why?
| Oncogene Proteins, Viral | 1 | 2001 | 52 | 0.010 |
Why?
| Skin Transplantation | 1 | 2001 | 43 | 0.010 |
Why?
| Papillomaviridae | 1 | 2001 | 103 | 0.010 |
Why?
| Tumor Cells, Cultured | 1 | 2001 | 457 | 0.010 |
Why?
| Graft Rejection | 1 | 2001 | 172 | 0.010 |
Why?
| Mice, Transgenic | 1 | 2001 | 540 | 0.010 |
Why?
| Gastrointestinal Diseases | 1 | 2000 | 125 | 0.010 |
Why?
| Radiography | 1 | 2000 | 485 | 0.010 |
Why?
| Haloperidol | 1 | 1999 | 47 | 0.010 |
Why?
| Cross-Over Studies | 1 | 1999 | 228 | 0.010 |
Why?
| Drug Administration Schedule | 1 | 1999 | 370 | 0.010 |
Why?
| Cells, Cultured | 1 | 2001 | 1571 | 0.010 |
Why?
| Double-Blind Method | 1 | 1999 | 708 | 0.010 |
Why?
| Mice, Inbred C57BL | 1 | 2001 | 1808 | 0.010 |
Why?
| Retrospective Studies | 1 | 2008 | 6272 | 0.010 |
Why?
| Mice | 1 | 2001 | 5687 | 0.010 |
Why?
| Animals | 1 | 2001 | 13125 | 0.000 |
Why?
|
|
Dunn's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|